NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Back to dashboard
Company Information
About this company
Key people
Adam H. Rogers
Chairman of the Board, President, Chief Executive Officer
Keith A. Vendola
Chief Financial Officer
Daniel D. Mikol
Chief Medical Officer
Brian Eric Bayley
Independent Director
Randall E. Kaye
Independent Director
Neil A. Klompas
Independent Director
Krista L. Mckerracher
Independent Director
Harold Martin Punnett
Independent Director
Click to see more
Key facts
- Shares in issue107.52m
- EPICNGEN
- ISINCA64082X2032
- LocationCanada
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$199.99m
- Employees10
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.